A prior parasite infection trained lung macrophages to protect mice from lethal flu

The experiment is a heterologous challenge. The team infected mice with the nematode Nippostrongylus brasiliensis, waited four to six weeks for that response to resolve, then gave them a lethal dose of H1N1 influenza ^[3]. Worm and virus are unrelated, so surviving the flu cannot be residual flu-specific immunity.

The protection traced to a small population of interstitial macrophages the authors call NAMs, for nerve- and airway-associated macrophages. They are CD169-positive, they sit around large airways and pulmonary nerves in both mice and humans, and they already run wound-repair, immunoregulatory and efferocytosis programs ^[1]. A worm infection drives type 2 inflammation, and after it these cells expand ^[2]. Alveolar macrophages, the lung's better-known resident population, die off in large numbers after influenza or SARS-CoV-2; NAMs instead expand early ^[15].

What rules out the obvious explanation is the viral count. Conditioned mice did not clear more virus, and their T cell responses were no stronger ^[5]. They lived anyway, while every unconditioned control was dead by day five or six ^[4]. The protected lungs showed less immunopathology, more clearing of dead cells, and faster repair ^[6]. The paper's term for this is disease tolerance: limiting immune-mediated damage without any change in pathogen load ^[11].

The causal test is the part I would weigh most. In mice engineered so the researchers could delete NAMs on command, removing the conditioned cells, or replacing them with unconditioned ones, abolished the survival benefit ^[7]. Transferring conditioned NAMs into naive mice handed over the tolerance, again without improving viral clearance ^[8].

Underneath sits a chromatin program built on IL-4, STAT6, PPAR-gamma and ARG1 that locks the cells into a pro-resolving, reparative state ^[9]. Trained immunity is a durable epigenetic and metabolic reprogramming of innate cells after a first stimulus ^[14]. This version is local, in the tissue. Most trained-immunity work instead reprograms bone marrow precursors to improve pathogen control ^[13].

Whether any of it protects a person is unproven. Every survival number here is from mice ^[4]. The human evidence is a meta-analysis of lung single-cell atlases from healthy people and patients with idiopathic pulmonary fibrosis and COPD, which found NAM-like repair programs that switch on depending on context ^[10]. That shows the cell state exists in human lungs. Whether it carries anyone through influenza is another question.

The authors present the trained-macrophage state as a therapeutic entry point for severe inflammatory respiratory infection, separate from drugs that lower viral load ^[16]. The rationale is clinical: severe respiratory viral disease varies widely between people and often reflects immunopathology rather than a failure to control the pathogen ^[12].